CONCISE REPORT

Exposure to passive smoking and rheumatoid arthritis risk: results from the Swedish EIRA study

Anna Karin Hedström,1,2 Lars Klareskog,3 Lars Alfredsson2,4

ABSTRACT

Introduction Smoking has consistently been associated with increased risk of developing rheumatoid arthritis (RA). The aim of this study was to estimate the influence of passive smoking on the risk of developing anti-cyclic citrullinated peptide antibodies (ACPA)-positive and ACPA-negative RA.

Methods A population-based case–control study using incident cases of RA was performed in Sweden, and the study population in this report was restricted to include never-smokers (589 cases, 1764 controls). The incidence of RA among never-smokers who had been exposed to passive smoking was compared with that of never-smokers who had never been exposed, by calculating the OR with a 95% CI employing logistic regression.

Results No association was observed between exposure to passive smoking and RA risk (OR 1.0, 95% CI 0.8 to 1.2 for ACPA-positive RA, and OR 0.9, 95% CI 0.7 to 1.2, for ACPA-negative RA). No suggestion of a trend between duration of passive smoking and RA risk was observed.

Discussions No association was observed between exposure to passive smoking and RA risk, which may be explained by a threshold below which no association between smoke exposure and RA occurs.

INTRODUCTION

Rheumatoid arthritis (RA) is systemic inflammatory disease characterised by progressive joint destruction and autoantibody formation. Based on serological features, RA can be divided into anti-cyclic citrullinated peptide antibodies (ACPA)-positive and ACPA-negative subsets.1 Disease susceptibility is determined by a complex interplay between genetic and environmental factors, and both retrospective and prospective studies have demonstrated that smoking is one of the major environmental factors in RA development.2-4 Smoking has been observed to induce citrullination of peptide antigens in the lungs6 and has been reported to be an important factor for the development of RA in the ACPA-positive subset.2

No studies have been performed investigating the effect of environmental tobacco smoke on RA risk. However, maternal smoking during pregnancy has been reported to increase the risk of inflammatory polyarthropathies and juvenile RA in female offspring.9 The effect of environmental tobacco smoke on disease activity in RA has been investigated in a multicentre longitudinal observational study of patients with RA, and no impact of passive smoking on disease activity was observed among never-smoking patients with RA.9 Using a large Swedish population-based case–control study we thus aimed to examine whether exposure to passive smoking influences the risk of developing ACPA-positive and ACPA-negative RA.

METHODS

Study design and study subjects

This report was based on data from the ongoing project Epidemiological Investigation of Rheumatoid Arthritis (EIRA) which is a population-based case–control study comprising the population aged 18–70 years in the middle and southern parts of Sweden. All hospital-based and most privately run rheumatology units participated in recruiting incident cases to the study. All cases fulfilled the American College of Rheumatology 1987 criteria. For each case, two controls were randomly selected from the national population register, matched by age, gender and residential area. A more detailed description of the study design can be found elsewhere.10

During the study period October 2005 to September 2014, completed questionnaires were obtained from 1652 cases and 3553 controls, the response proportion being 92% for the cases and 75% for the controls.

Anti-cyclic citrullinated peptide antibodies

ACPA status among cases was analysed using Immunoscan-RA Mark2 ELISA test (anti-CCP2 test). An antibody level exceeding 25 AU/mL was regarded as ACPA positivity.

Data collection

Information regarding lifestyle factors and different exposures was collected using a standardised questionnaire. Information on smoking was obtained by asking about current and previous smoking habits, and information on exposure to passive smoking was obtained by asking if the subject had been daily exposed to passive smoking at home or at work, and if so, during what period or periods in life.

For each case, the time of the initial appearance of RA symptoms was used as an estimate of the disease onset, and the year in which this occurred was defined as the index year. The corresponding controls were given the same index year. Information regarding smoking and exposure to passive smoking was considered prior to or during the index year in the cases and during the same period of time in the corresponding controls.

All ever-smokers were excluded (1063 cases and 1789 controls). Never-smokers who reported exposure to passive smoking prior to index were
defined as exposed whereas those who reported that they had never been exposed to passive smoking were defined as never exposed. Exposed subjects were also divided into groups based on whether the exposure occurred within 10 years prior to index or earlier in life. In order to analyse the influence of duration of exposure to passive smoking on the risk of developing the disease, we categorised the exposed subjects into groups based on the duration of exposure prior to index.

### Statistical analysis

Among never-smokers, subjects exposed to passive smoking were compared with those that reported never having been exposed to passive smoking with regard to occurrence of RA, by calculating ORs with 95% CIs employing logistic regression. Trend test for a dose–response relationship regarding duration of passive smoking and risk of both subsets of RA was performed by using a continuous variable for duration of passive smoking (years) in a logistic regression model.

Both matched and unmatched analyses were carried out. The results from the unmatched analyses were in close agreement with those from the matched analyses but had a higher degree of precision due to a substantial loss of cases and controls in the matched analyses.

All analyses were adjusted for age, gender, residential area and ancestry. Assessment of ancestry was based on whether the subject was born in Scandinavia or not, and whether either of the subject’s parents had immigrated to Scandinavia. A subject who was born in Scandinavia, whose parents had not immigrated, was classified as Scandinavian. Adjustments were also made for educational level (university degree or not), alcohol consumption (number of drinks per week at study inclusion) and body mass index at inclusion in the study (more or less than 25 kg/m²). However, these factors had a minor influence on the results and were not retained in the final analyses. All analyses were conducted using SAS V.9.2.

### RESULTS

Our analyses of passive smoking and RA risk among never-smokers included 589 cases and 1764 controls. Overall, the proportion that had been exposed to passive smoking prior to the index year was 47% among ACPA-positive cases, 48% among ACPA-negative cases and 50% among controls. Characteristics of cases and controls are presented in table 1.

No association was observed between exposure to passive smoking and risk of ACPA-positive or ACPA-negative RA, regardless if the exposure took place within 10 years prior to index or earlier in life. Compared with those who had never been exposed to passive smoking, the OR was 1.0 (95% CI 0.7 to 1.2) for ACPA-positive RA and 0.9 (95% CI 0.7 to 1.2) for ACPA-negative RA among those ever exposed to passive smoking (table 2). The results from the matched analysis are presented in online supplementary table 1. There were no significant age-related or gender-related differences. There was no suggestion of a trend between duration of passive smoking and RA risk. Long-term exposure to passive smoking for 20 years or longer was not significantly associated with increased disease susceptibility (table 3).

### DISCUSSION

According to our observations among never-smokers, exposure to passive smoking did not increase the risk of ACPA-positive or ACPA-negative RA. The present result of a lack of association between passive smoking and risk for RA may be due to the previously described threshold for exposure to smoke, where no association between risk for RA and active smoking was seen when the accumulated amount of smoking was low enough.10 However, we only had information on duration but not intensity of exposure to passive smoking and we were therefore unable to calculate the cumulative dose of passively inhaled smoke in order to study a dose–response correlation.11 Although exposure to passive smoking does not seem to be a risk factor for RA, we cannot rule out that extensive exposure to passive smoking could affect disease risk.

Our study was designed as a case–control study with incident cases, and information regarding smoking habits and exposure to passive smoking was collected retrospectively. Recall bias was minimised by using incident cases of RA. The mean duration

---

**Table 1** Characteristics of cases and controls

<table>
<thead>
<tr>
<th></th>
<th>ACPA-positive cases</th>
<th>ACPA-negative cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposed to passive smoking, n (%)</td>
<td>180 (47)</td>
<td>98 (48)</td>
<td>876 (50)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>301 (78)</td>
<td>137 (67)</td>
<td>1293 (73)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>84 (22)</td>
<td>67 (33)</td>
<td>471 (27)</td>
</tr>
<tr>
<td>Scandinavian, n (%)</td>
<td>333 (86)</td>
<td>185 (91)</td>
<td>1533 (87)</td>
</tr>
<tr>
<td>Mean age at disease onset (SD)</td>
<td>52.8 (16.0)</td>
<td>47.8 (15.3)</td>
<td></td>
</tr>
<tr>
<td>Disease duration since first symptom (SD)</td>
<td>0.8 (1.1)</td>
<td>0.9 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Total, n</td>
<td>385</td>
<td>204</td>
<td>1764</td>
</tr>
</tbody>
</table>

ACPA, anti-cyclic citrullinated peptide antibodies.

**Table 2** OR with 95% CI of developing rheumatoid arthritis (RA) for subjects exposed to passive smoking compared with those who have never been exposed

<table>
<thead>
<tr>
<th>Exposure to passive smoking</th>
<th>ACPA-positive RA</th>
<th>ACPA-negative RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ca/co</td>
<td>OR (95% CI)*</td>
</tr>
<tr>
<td>Never</td>
<td>205/888</td>
<td>1.0 (reference)</td>
</tr>
<tr>
<td>Ever</td>
<td>180/876</td>
<td>1.0 (0.8 to 1.2)</td>
</tr>
<tr>
<td>Within 10 years prior to index</td>
<td>45/170</td>
<td>1.1 (0.8 to 1.7)</td>
</tr>
<tr>
<td>Before 10 years prior to index</td>
<td>135/706</td>
<td>0.9 (0.7 to 1.2)</td>
</tr>
</tbody>
</table>

All subjects were never-smokers.

*Adjusted for age, gender, residential area and ancestry.

ACPA, anti-cyclic citrullinated peptide antibodies; ca/co, number of exposed cases and controls.

**Table 3** OR with 95% CI of developing rheumatoid arthritis (RA) for subjects exposed to passive smoking compared with those who have never been exposed, by duration of exposure

<table>
<thead>
<tr>
<th>Duration of exposure to passive smoking (years)</th>
<th>ACPA-positive RA</th>
<th>ACPA-negative RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ca/co</td>
<td>OR (95% CI)*</td>
</tr>
<tr>
<td>0</td>
<td>205/897</td>
<td>1.0 (reference)</td>
</tr>
<tr>
<td>1–9</td>
<td>52/221</td>
<td>1.0 (0.7–1.5)</td>
</tr>
<tr>
<td>10–19</td>
<td>66/319</td>
<td>1.0 (0.7–1.3)</td>
</tr>
<tr>
<td>20+</td>
<td>616/325</td>
<td>0.9 (0.7–1.3)</td>
</tr>
</tbody>
</table>

Values for trend 0.8

All subjects were never-smokers.

*Adjusted for age, gender, residential area and ancestry.

ACPA, anti-cyclic citrullinated peptide antibodies; ca/co, number of exposed cases and control.
from the disease onset to inclusion in the study was <1 year in both subgroups. We took great effort to obtain information on lifestyle factors and environmental exposures in an identical way for the cases and the controls. Furthermore, the questionnaire contained a wide range of questions regarding many potential environmental risk factors and no section in the questionnaire was given prime focus. A potential selection bias may arise when recruiting cases and controls. The proportion of respondents with regard to participation in EIRA was 92% for cases and 75% for controls. Since the structure of the Swedish public healthcare system provides equal access to medical services for all Swedish citizens, almost all cases of RA are referred to public rheumatology units and it is not likely that the few unidentified cases would cause a substantial bias in our calculations. Selection bias among controls is likely to be modest since the prevalence of smoking among the general population at equivalent ages. When observing no association between exposure and disease, as in our study, it is of interest to know what strengths of association the study had a reasonably power to detect. Comparing ever exposed to passive smoking to never exposed, our study had the power (≥80) to identify an OR of 1.33 for ACPA-positive RA and 1.45 for ACPA-negative RA. In summary, in this population-based case–control study of RA, no association was observed between exposure to passive smoking and risk of ACPA-positive or ACPA-negative RA among never-smokers. Our finding may be explained by a threshold below which no association between smoke exposure and RA occurs.

Contributors Conception and design of the study, and acquisition of data: LA and LK. Analysis of data and drafting of the manuscript and tables: AKH. All authors revised the manuscript for important intellectual content.

Funding The EIRA study was supported by grants from the Swedish Medical Research Council, the Swedish Council for Health, Working Life and Welfare, King Gustaf V’s 80-year foundation, the Swedish Rheumatism Foundation, Stockholm County Council, the insurance company AFA and the IMU-supported BeTheCure projects.

Competing interests None declared.

Patient consent Not required.

Ethics approval The ethics committee of the Karolinska Institutet.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES